Shares of nano-cap company Polyrizon Ltd. (PLRZ) surged over 200% on Wednesday morning after the company announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a European-based Good Manufacturing Practice (GMP) manufacturer.

PLRZ is currently trading at $3.1998, up $2.1498 or 204.8600%, on the Nasdaq. The stock opened its trading at $2.5000 after closing Tuesday at $1.0500. The stock has traded between $0.7700 and $3.4000 in the past 52-week period.

This collaboration will supply Clinical Trial Material (CTM) for Polyrizon's PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.

With this agreement, which was announced earlier this month, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial.

For comments and feedback contact: [email protected]